Ibex Biosciences has a total of 36 patents globally, out of which 1 has been granted. Of these 36 patents, more than 88% patents are active. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Ibex Biosciences.
Ibex Biosciences was founded in the year 2015. The Company works on many different projects to find solutions for big problems in health and the environment. They try out new ideas and processes that haven’t been proven by other researchers yet.
Do read about some of the most popular patents of Ibex Biosciences which have been covered by us in this article and also you can find Ibex Biosciences patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Ibex Biosciences patent portfolio.
How many patents does Ibex Biosciences have?
Ibex Biosciences has a total of 36 patents globally. These patents belong to 5 unique patent families. Out of 36 patents, 32 patents are active.
How Many Patents did Ibex Biosciences File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Ibex Biosciences Applications Filed | Ibex Biosciences Patents Granted |
| 2023 | 2 | 1 |
| 2022 | 11 | – |
| 2021 | 1 | – |
| 2020 | 8 | – |
| 2019 | 14 | – |
How many Ibex Biosciences patents are Alive/Dead?
How Many Patents did Ibex Biosciences File in Different Countries?
Countries in which Ibex Biosciences Filed Patents
| Country | Patents |
| Israel | 4 |
| Europe | 4 |
| Australia | 4 |
| United States Of America | 4 |
| Canada | 4 |
| China | 4 |
| India | 3 |
| African Regional Industrial Property Organization | 1 |
| Mexico | 1 |
| Brazil | 1 |
| South Africa | 1 |
| South Korea | 1 |
Where are Research Centres of Ibex Biosciences Patents Located?
What Percentage of Ibex Biosciences US Patent Applications were Granted?
Ibex Biosciences (Excluding its subsidiaries) has filed 3 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0.0%.
Below are the key stats of Ibex Biosciences patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Ibex Biosciences?
| Law Firm | Total Applications | Success Rate |
| Cooley Llp | 3 | 0% |
List of Ibex Biosciences Patents
| Ibex Biosciences Patents | Title |
| US20240010723A1 | Antibodies Targeted To Cd147 |
| US20220228126A1 | Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis |
| US20220025025A1 | Antibodies Directed To Filamin-A And Therapeutic Uses Thereof |
| US20210113714A1 | Use Of Pcbp1 To Treat Hyperproliferative Disease |
| EP4274615A1 | Antibodies Targeted To Cd147 |
| EP4010471A4 | Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis |
| EP3863687A4 | Antibodies Directed To Filamin-A And Therapeutic Uses Thereof |
| EP3749763A4 | Use Of Pcbp1 To Treat Hyperproliferative Disease |
| CN113164633B | Antibodies Against Filamin-A And Their Therapeutic Uses |
| CN116887861A | Antibodies Targeting Cd147 |
| CN114402072A | Application Of Pcbp1 To Generation Of Induced Pluripotent Stem Cells And Inhibition Of Tumorigenesis |
| CN111757933A | Use Of Pcbp1 To Treat Hyperproliferative Disease |
| IL304093A | Antibodies Targeted To Cd147 |
| AU2022205427A1 | Antibodies Targeted To Cd147 |
| CA3204047A1 | Antibodies Targeted To Cd147 |
| IL290162A | Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis |
| AU2020325311A1 | Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis |
| IL281932A | Antibodies Directed To Filamin-A And Therapeutic Uses Thereof |
| AU2019358060A1 | Antibodies Directed To Filamin-A And Therapeutic Uses Thereof |
| CA3149640A1 | Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis |
| IL276382A0 | Use Of Pcbp1 To Treat Hyperproliferative Disease |
| AU2019215464A1 | Use Of Pcbp1 To Treat Hyperproliferative Disease |
| CA3115077A1 | Antibodies Directed To Filamin-A And Therapeutic Uses Thereof |
| CA3089731A1 | Use Of Pcbp1 To Treat Hyperproliferative Disease |
| IN202247011039A | Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis |
| IN202147020127A | Antibodies Directed To Filamin-A And Therapeutic Uses Thereof |
| IN202047037165A | Use Of Pcbp1 To Treat Hyperproliferative Disease |
| KR1020230131478A | Antibodies Targeting Cd147 |
| BR112023013543A2 | Antibodies Targeted To Cd147 |
| APP2023015045A0 | Antibodies Targeted To Cd147 |
| ZA202306655A | Antibodies Targeted To Cd147 |
| MX2020008243A | Use Of Pcbp1 To Treat Hyperproliferative Disease. |
| WO2022150759A1 | Antibodies Targeted To Cd147 |
| WO2021026488A3 | Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis |
| WO2020076954A1 | Antibodies Directed To Filamin-A And Therapeutic Uses Thereof |
| WO2019153008A1 | Use Of Pcbp1 To Treat Hyperproliferative Disease |
What are Ibex Biosciences key innovation segments?
What Technologies are Covered by Ibex Biosciences?
The chart below distributes patents filed by Ibex Biosciences